EXTEND-IA DNase: Dornase Alfa in Acute Ischemic Stroke

Phase 2, open-label, single-arm trial of dornase alfa in ischemic stroke, sponsored by University of Melbourne. Primary endpoint: Proportion of patients with substantial angiographic reperfusion or absence of retrievable intracranial thrombus at initial angiogram without symptomatic intracerebral hemorrhage at 24 hours. Started Feb 2022; status: completed.